03/30/2026
🚨 Major news for type 2 diabetes today! 🚨
Awiqli (insulin icodec), a once-weekly basal insulin made by Novo Nordisk, has just been approved by the FDA! This will be the first once-weekly basal insulin available in the U.S. for adults with type 2 diabetes.
This news is huge—it will offer people with type 2 diabetes more options for their basal insulin and remove the burden of daily injections for many. This new option could be a better fit for millions of people. We're thrilled to see this progress!
Additionally, the FDA-approved label includes time in range for the very first time in U.S. history, a major milestone in how we measure and communicate glucose management. diaTribe is particularly excited about this news, as the Time in Range Coalition has been working tirelessly to advance time in range as a widely used metric across people with diabetes, healthcare professionals, and regulatory bodies.
Read more about the approval at https://diatribenews.org/4bOTar1.